Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma

Neoplasma

Volumn 55, Issue 2, 2008, Pages 107-112

  Vranovsky, A ^a   Ladicka, M ^a   Lakota, J ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Autologous transplantation, aggressive non Hodgkin's lymphoma; High dose chemotherapy

Indexed keywords

ACICLOVIR; BLEOMYCIN; CARMUSTINE; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; OFLOXACIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; DHAP PROTOCOL; MACOP B REGIMEN; MACOP-B REGIMEN; PREDNISOLONE;

ADULT; ALK NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFICACY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ARREST; HUMAN; LARGE CELL LYMPHOMA; LIVER VEIN OBSTRUCTION; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; SEPTIC SHOCK; THROMBOCYTOPENIA; TREATMENT OUTCOME; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 48549101468     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. The Non-Hodgkin's Lymphoma Classification Project. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. Blood 1997; 89: 3909-3918.
2. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
3. HARRIS NL, JAFFE ES, DIEBOLD J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
4. LISTER TA, CROWTHER D, SUTCLIFFE SB, et al. Report of a committee convened to discuss evaluation and staging of Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
5. KLIMO P, CONNORS JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602. (Pubitemid 15120476)
6. CHESON BD, HORNING SJ, COIFFIER B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
7. KAPLAN E AND MEIER P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
8. GREB A, BOHLIUS J, TRELLE S, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - Results of a comprehensive meta-analysis. Cancer Treatment Reviews 2007; 33: 338-346. (Pubitemid 46778207)
9. WITZIG EW. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23: 6409-6414. (Pubitemid 46222241)
10. VERDONCK LF, VAN PUTTEN WLJ, HAGENBEEK A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045-1051.
11. KLUIN-NELEMANS HC, ZAGONEL V, ANASTASOPOULOU A, et al. Standard chemotherapy with or without chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC Study. Journal Natl Cancer Inst 2001; 93: 22-30. (Pubitemid 32060886)
12. GISSELBRECHT C, LEPAGE E, MOLINA T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472-2479. (Pubitemid 34525732)
13. KAISER U, UEBELACKER I, ABEL U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for aggressive lymphoma. J Clin Oncol 2002; 20: 4413-4419.
14. MARTELLI M, GHERLINZONI F, DE RENzo A,et al.. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial. J Clin Oncol 2003; 21: 1255-1262.
15. OLIVIERI A, SANTINI G, PATTI C, et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: Long-term results by the NHLCSG. Ann Oncol 2005; 16: 1941-1948.
16. HAIOUN C, LEPAGE E, GISSELBRECHT, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2 Groupe d'Etude des Lyphomes de l'Adulte. J Clin Oncol 1997; 15: 1131-1137.
17. GIANNI AM, BREGNI M, SIENA S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297. (Pubitemid 27187782)
18. SANTINI G, SALVAGNO L, LEONI P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796-2802.
19. MILPIED N, DECONINCK E, GUILLARD F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295
20. COIFFIER B, LEPAGE E, BRIERE J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
21. HABERMANN TM, WELLER EA, MORRISON VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24: 3121-3127. (Pubitemid 46638950)
22. PFREUNDSCHUH M, TRUMPER L, OSTERBORG A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MinT) Group. Lancet Oncol 2006;7:379-391.
23. SEHN LH, DONALDSON J, CHHANABHAI M, et al. Introduction of combined CHOP plus rituximab dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
24. SEHN LH, BERRY B, CHHANABHAI M, et al. The revised International Prognostic Index (IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109: 1857-1861.